Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03440736
Brief Title: Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome (METABOLYX)

First Submitted : January 31, 2018
First Submitted that Met QC Criteria : February 19, 2018
First Posted : February 22, 2018

Last Update Submitted that Met QC Criteria : April 30, 2021
Last Update Posted : May 4, 2021